• EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, tasking him with leading commercial strategy and launch preparation for DURAVYU, the company’s Phase 3 wet age-related macular degeneration and diabetic macular edema candidate.
• Campbell’s long history of building ophthalmology franchises and launching eye-care products at companies such as Genentech, Novartis, Shire, and Opthea could materially shape how EyePoint brings DURAVYU to market.
• Now we’ll examine how bringing in an experienced ophthalmology commercial leader may influence EyePoint’s investment narrative centered on DURAVYU.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

EyePoint Investment Narrative Recap

To own EyePoint today, you need to believe DURAVYU can progress through Phase 3 and eventually convert a largely single-asset, loss-making story into a commercial retina franchise. The biggest near term catalyst remains DURAVYU’s pivotal data and regulatory path, while the main risk is continued high cash burn with minimal current revenue. Campbell’s appointment does not change these fundamentals, but it could influence how effectively EyePoint executes if DURAVYU reaches launch.

Among recent updates, the October 2025 US$150 million follow on equity financing stands out alongside the DURAVYU program. It highlighted how dependent EyePoint is on external capital to fund Phase 3 trials and commercial build out, at a time when quarterly net revenue was about US$1 million and operating expenses exceeded US$60 million. Campbell’s hire now sits on top of this heavier cost base, raising the stakes for DURAVYU’s clinical and commercial outcomes.

Yet investors should also weigh how prolonged high expenses, minimal revenue, and any delay to DURAVYU data could pressure EyePoint’s cash runway and future dilution risk that investors should be aware of...

EyePoint's narrative projects $146.7 million in revenue and $34.1 million in earnings by 2028.

Uncover how EyePoint's forecasts yield a $36.08 fair value, a 142% upside to its current price.

Exploring Other Perspectives

Some of the lowest analyst estimates painted a far harsher picture, with revenue growth at only 7.9% a year and earnings still negative, so Campbell’s arrival may eventually shift how you compare that more cautious view against a story built around a single, still unproven late stage asset.

Explore 4 other fair value estimates on EyePoint - why the stock might be worth over 7x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.